Do analysts rate EVAX or ADXN?

Evaxion A/S currently has a consensus price target of $11.00, suggesting a potential upside of 243.75%. Given Evaxion A/S's stronger consensus rating and higher possible upside, analysts clearly believe Evaxion A/S is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EVAX or ADXN more profitable?

Evaxion A/S's return on equity of -73.56% beat Addex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -73.56% -37.45% Addex Therapeutics N/A -134.75% -105.99%

Do analysts prefer ADXN or KYNB?

Kyntra Bio has a consensus price target of $30.00, suggesting a potential upside of 310.40%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts prefer ADXN or GRML?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Greenland Mines Ltd. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ADXN or GRML more profitable?

Greenland Mines Ltd. Common Stock's return on equity of -109.40% beat Addex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Addex Therapeutics N/A -134.75% -105.99% Greenland Mines Ltd. Common Stock N/A -109.40% -98.80%

Does the media refer more to ADXN or GRML?

In the previous week, Addex Therapeutics had 1 more articles in the media than Greenland Mines Ltd. Common Stock. MarketBeat recorded 9 mentions for Addex Therapeutics and 8 mentions for Greenland Mines Ltd. Common Stock. Addex Therapeutics' average media sentiment score of 0.52 beat Greenland Mines Ltd. Common Stock's score of 0.31 indicating that Addex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Addex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Greenland Mines Ltd. Common Stock 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ADXN or BRNS?

Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 505.51%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Barinthus Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ADXN or BRNS more profitable?

Barinthus Biotherapeutics' return on equity of -63.83% beat Addex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Addex Therapeutics N/A -134.75% -105.99% Barinthus Biotherapeutics N/A -63.83% -48.77%

Do analysts recommend ADXN or DYAI?

Dyadic International has a consensus price target of $3.00, indicating a potential upside of 240.91%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media refer more to ADXN or DYAI?

In the previous week, Addex Therapeutics had 5 more articles in the media than Dyadic International. MarketBeat recorded 9 mentions for Addex Therapeutics and 4 mentions for Dyadic International. Addex Therapeutics' average media sentiment score of 0.52 beat Dyadic International's score of 0.48 indicating that Addex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Addex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Addex Therapeutics (ADXN) Competitors

$6.10 +0.04 (+0.58%)

As of 04:00 PM Eastern

Compare

ADXN vs. EVAX, KYNB, GRML, BRNS, and DYAI

Should you buy Addex Therapeutics stock or one of its competitors? MarketBeat compares Addex Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Addex Therapeutics include Evaxion A/S (EVAX), Kyntra Bio (KYNB), Greenland Mines Ltd. Common Stock (GRML), Barinthus Biotherapeutics (BRNS), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry.

How does Addex Therapeutics compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

In the previous week, Addex Therapeutics had 8 more articles in the media than Evaxion A/S. MarketBeat recorded 9 mentions for Addex Therapeutics and 1 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 1.89 beat Addex Therapeutics' score of 0.52 indicating that Evaxion A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Evaxion A/S	Very Positive
Addex Therapeutics	Positive

Evaxion A/S currently has a consensus price target of $11.00, suggesting a potential upside of 243.75%. Given Evaxion A/S's stronger consensus rating and higher possible upside, analysts clearly believe Evaxion A/S is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Evaxion A/S's return on equity of -73.56% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Addex Therapeutics	N/A	-134.75%	-105.99%

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Evaxion A/S has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Evaxion A/S has higher revenue and earnings than Addex Therapeutics. Evaxion A/S is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.54	-$7.71M	-$1.47	N/A
Addex Therapeutics	$210K	35.76	-$8.12M	-$5.74	N/A

Summary

Evaxion A/S beats Addex Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Addex Therapeutics compare to Kyntra Bio?

Addex Therapeutics (NASDAQ:ADXN) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Kyntra Bio has a consensus price target of $30.00, suggesting a potential upside of 310.40%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Addex Therapeutics had 8 more articles in the media than Kyntra Bio. MarketBeat recorded 9 mentions for Addex Therapeutics and 1 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.94 beat Addex Therapeutics' score of 0.52 indicating that Kyntra Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Addex Therapeutics	Positive
Kyntra Bio	Positive

Kyntra Bio has a net margin of 2,199.13% compared to Addex Therapeutics' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-134.75%	-105.99%
Kyntra Bio	2,199.13%	N/A	-36.71%

Addex Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Kyntra Bio has higher revenue and earnings than Addex Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	35.76	-$8.12M	-$5.74	N/A
Kyntra Bio	$6.44M	4.60	$183.45M	$40.46	0.18

Summary

Kyntra Bio beats Addex Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Addex Therapeutics compare to Greenland Mines Ltd. Common Stock?

Addex Therapeutics (NASDAQ:ADXN) and Greenland Mines Ltd. Common Stock (NASDAQ:GRML) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 20.1% of Greenland Mines Ltd. Common Stock shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Comparatively, 11.3% of Greenland Mines Ltd. Common Stock shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Addex Therapeutics has higher revenue and earnings than Greenland Mines Ltd. Common Stock. Addex Therapeutics is trading at a lower price-to-earnings ratio than Greenland Mines Ltd. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	35.76	-$8.12M	-$5.74	N/A
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A

In the previous week, Addex Therapeutics had 1 more articles in the media than Greenland Mines Ltd. Common Stock. MarketBeat recorded 9 mentions for Addex Therapeutics and 8 mentions for Greenland Mines Ltd. Common Stock. Addex Therapeutics' average media sentiment score of 0.52 beat Greenland Mines Ltd. Common Stock's score of 0.31 indicating that Addex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Greenland Mines Ltd. Common Stock	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Greenland Mines Ltd. Common Stock's return on equity of -109.40% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-134.75%	-105.99%
Greenland Mines Ltd. Common Stock	N/A	-109.40%	-98.80%

Addex Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Greenland Mines Ltd. Common Stock has a beta of 6.97, suggesting that its share price is 597% more volatile than the broader market.

Summary

Addex Therapeutics and Greenland Mines Ltd. Common Stock tied by winning 5 of the 10 factors compared between the two stocks.

How does Addex Therapeutics compare to Barinthus Biotherapeutics?

Addex Therapeutics (NASDAQ:ADXN) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by company insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Addex Therapeutics has higher earnings, but lower revenue than Barinthus Biotherapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	35.76	-$8.12M	-$5.74	N/A
Barinthus Biotherapeutics	$14.97M	1.80	-$66.43M	-$1.29	N/A

In the previous week, Addex Therapeutics had 7 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 9 mentions for Addex Therapeutics and 2 mentions for Barinthus Biotherapeutics. Addex Therapeutics' average media sentiment score of 0.52 beat Barinthus Biotherapeutics' score of 0.43 indicating that Addex Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Addex Therapeutics	Positive
Barinthus Biotherapeutics	Neutral

Barinthus Biotherapeutics' return on equity of -63.83% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-134.75%	-105.99%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 505.51%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Addex Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.4, meaning that its share price is 140% less volatile than the broader market.

Summary

Barinthus Biotherapeutics beats Addex Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Addex Therapeutics compare to Dyadic International?

Addex Therapeutics (NASDAQ:ADXN) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Addex Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Dyadic International has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

Dyadic International has higher revenue and earnings than Addex Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	35.76	-$8.12M	-$5.74	N/A
Dyadic International	$3.09M	10.38	-$7.36M	-$0.23	N/A

16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by company insiders. Comparatively, 20.9% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Addex Therapeutics had 5 more articles in the media than Dyadic International. MarketBeat recorded 9 mentions for Addex Therapeutics and 4 mentions for Dyadic International. Addex Therapeutics' average media sentiment score of 0.52 beat Dyadic International's score of 0.48 indicating that Addex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Addex Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Addex Therapeutics' return on equity of -134.75% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-134.75%	-105.99%
Dyadic International	-192.40%	-1,005.45%	-77.64%

Dyadic International has a consensus price target of $3.00, indicating a potential upside of 240.91%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Dyadic International beats Addex Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Addex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADXN vs. The Competition

Export

Metric	Addex Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.48M	$3.06B	$6.84B	$12.43B
Dividend Yield	N/A	1.87%	2.67%	6.11%
P/E Ratio	N/A	19.67	25.83	24.36
Price / Sales	35.76	358.40	511.51	84.16
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	1.31	4.25	10.98	6.49
Net Income	-$8.12M	$64.45M	$3.57B	$336.61M
7 Day Performance	-0.72%	4.17%	3.06%	0.90%
1 Month Performance	-12.14%	1.44%	0.72%	-0.36%
1 Year Performance	-31.85%	34.07%	36.82%	31.26%

Addex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADXN Addex Therapeutics	0.7493 of 5 stars	$6.11 +0.6%	N/A	-32.3%	$7.48M	$210K	N/A	30	Earnings Report Short Interest Decrease
EVAX Evaxion A/S	3.1709 of 5 stars	$3.46 +1.9%	$11.00 +218.4%	+26.1%	$28.82M	$7.53M	N/A	60	Positive News Gap Up
KYNB Kyntra Bio	4.1083 of 5 stars	$6.93 -0.6%	$30.00 +332.9%	N/A	$28.05M	$7.44M	0.17	570
GRML Greenland Mines Ltd. Common Stock	0.9167 of 5 stars	$0.23 -11.0%	N/A	-64.5%	$27.63M	N/A	N/A	5	Gap Up
BRNS Barinthus Biotherapeutics	2.1012 of 5 stars	$0.67 +0.4%	$4.00 +494.4%	-24.7%	$27.49M	N/A	N/A	107	Short Interest Increase Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADXN) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Addex Therapeutics (ADXN) Competitors

ADXN vs. EVAX, KYNB, GRML, BRNS, and DYAI

How does Addex Therapeutics compare to Evaxion A/S?

Summary

How does Addex Therapeutics compare to Kyntra Bio?

Summary

How does Addex Therapeutics compare to Greenland Mines Ltd. Common Stock?

Summary

How does Addex Therapeutics compare to Barinthus Biotherapeutics?

Summary

How does Addex Therapeutics compare to Dyadic International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN vs. The Competition

Addex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Addex Therapeutics (ADXN) Competitors

ADXN vs. EVAX, KYNB, GRML, BRNS, and DYAI

How does Addex Therapeutics compare to Evaxion A/S?

Does the media prefer EVAX or ADXN?

Do analysts rate EVAX or ADXN?

Is EVAX or ADXN more profitable?

Do insiders and institutionals hold more shares of EVAX or ADXN?

Which has more risk & volatility, EVAX or ADXN?

Which has preferable valuation and earnings, EVAX or ADXN?

Summary

How does Addex Therapeutics compare to Kyntra Bio?

Do analysts prefer ADXN or KYNB?

Do insiders and institutionals have more ownership in ADXN or KYNB?

Does the media favor ADXN or KYNB?

Is ADXN or KYNB more profitable?

Which has more volatility & risk, ADXN or KYNB?

Which has preferable earnings and valuation, ADXN or KYNB?

Summary

How does Addex Therapeutics compare to Greenland Mines Ltd. Common Stock?

Do insiders and institutionals hold more shares of ADXN or GRML?

Do analysts prefer ADXN or GRML?

Which has higher valuation and earnings, ADXN or GRML?

Does the media refer more to ADXN or GRML?

Is ADXN or GRML more profitable?

Which has more risk & volatility, ADXN or GRML?

Summary

How does Addex Therapeutics compare to Barinthus Biotherapeutics?

Do insiders & institutionals hold more shares of ADXN or BRNS?

Which has higher valuation & earnings, ADXN or BRNS?

Does the media refer more to ADXN or BRNS?

Is ADXN or BRNS more profitable?

Do analysts recommend ADXN or BRNS?

Which has more risk & volatility, ADXN or BRNS?

Summary

How does Addex Therapeutics compare to Dyadic International?

Which has more risk and volatility, ADXN or DYAI?

Which has stronger valuation & earnings, ADXN or DYAI?

Do insiders and institutionals have more ownership in ADXN or DYAI?

Does the media refer more to ADXN or DYAI?

Is ADXN or DYAI more profitable?

Do analysts recommend ADXN or DYAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN vs. The Competition

Addex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools